• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Medications for ED can harm optic nerve


Increasing use of erectile dysfunction (ED) drugs has added a new topic to the ophthalmologist-patient conversation: possible risks to the optic nerve in certain patients with glaucoma who are taking ED medications.

Key Points

Because of concerns that these ED drugs could harm the optic nerve, ophthalmologists need to discuss use of these medications with patients with glaucoma and urge caution in certain situations, said George A. Cioffi, MD, chief of ophthalmology, Devers Eye Institute, Legacy Health System, Portland, OR.

During the review of systems, physicians should ask their male patients whether they are taking ED medications. As a further step, they should encourage caution, at least in cases of small, crowded discs and discs with optic nerve drusen. Caution also should be urged in cases of glaucoma that may include a vascular relationship or in patients with repetitive optic nerve head hemorrhages that develop field defects, Dr. Cioffi said.

Use of these medications is increasing as ED is diagnosed in new patients in an aging population and because new indications unrelated to ED are being found. The main mechanism of action in ED drugs is inhibition of cyclic guanosine monophosphate (cGMP)-or, more specifically, phosphodiasterase type 5 (PDE5)-which is present in all vascular tissues.

Ophthalmologists should be aware of both the systemic and ocular side effects of ED medications, Dr. Cioffi said. Systemically, theoretical concerns of reduced myocardial tolerance to ischemia, as well as the potential to promote cardiac arrhythmias, exist, he continued.

"In the eye literature, most of the symptoms or side effects to these medications that have been described have been related not to PDE5 but to the weak inhibition of PDE6, which is in rods and cones," Dr. Cioffi explained. "This inhibition of this phosphodiasterase results in the transient blurred vision or blue-tinged vision that you may have heard about in the lay press.

"This is a dose-dependent response and is unrelated to what we think of in terms of the real side effect, and that is the PDE5 inhibition in circulatory abnormalities," he said. "To be honest, the ocular blood flow studies that have been done in this field are confusing and have very contradictory results."


PDE5 also has been associated with anterior ischemic optic neuropathy (AION), Dr. Cioffi continued. About 30 case reports have appeared in the literature, as well as several case reports of branch artery occlusion. These cases are temporary and are related to the use of sildenafil citrate or other inhibition molecules, but causality is difficult to find, he said.

"It's just that they were taken the night before, and patients often wake up with a change in their visual status the next morning," Dr. Cioffi explained. "Most of these cases have been related to the so-called disc at risk, or the crowded optic nerve.

"It's common, however, for these patients to regain 20/20 vision, although they do still have a deficit in the affected eye, often seen by a Marcus-Gunn pupil and peripheral vision loss," he added.

Look at risk factors

AION risk factors can include a small crowded disc, increasing age, hypertension, and diabetes. Many of these factors overlap with those for glaucoma, Dr. Cioffi said. In addition, the vascular supply that is at risk in glaucoma-the ciliary circulation that supplies the more posterior optic nerve-is the same vascular supply that apparently is insulted in AION.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
Orbis in-person training takes flight once again
Elkin: Talking about the importance of pediatric eye health and safety
© 2024 MJH Life Sciences

All rights reserved.